Errekappa Euroterapici S.p.A.

Errekappa Euroterapici S.p.A. is an Italian pharmaceutical company based in Milan. According to its official website, it has been active since 1989, when the current joint-stock company was incorporated, although the corporate history it recounts reaches back to the 1960s. The company describes itself as an Italian pharmaceutical firm committed to promoting innovative therapeutic solutions, and it presents its activity as spanning both pharmacological therapies and scientific nutrition. The company's roots are in the cardiovascular field, where it built an early reputation through the launch of active molecules such as amlodipine (marketed as Antacal), doxazosin (Normothen) and atenolol (Atenol). During the 2000s and early 2010s it continued to work in cardiovascular care, including fixed-dose combinations for hypertension, while also developing supplements such as Riscol Plus for dyslipidemias and Anasten Plus for asthenia. In 2004 it launched Erreflog, a nimesulide-based mouthwash. From 2007 onward Errekappa shifted increasing attention to clinical nutrition, developing products conceived as an interactive approach to malnutrition in patients with chronic conditions. Preclinical and clinical studies published in specialist journals supported the idea that a cluster of essential amino acids can positively influence the use of nutritional substrates, leading to the launch of Aminotrofic. In 2012 the company extended this work with Aminoglutam, a line of foods for special medical purposes aimed at malnutrition in acute and sub-acute patients. Today Errekappa positions itself as a point of reference in clinical nutrition and metabolic rehabilitation, addressing health professionals as well as consumers. Its product guide is organised around needs and conditions such as muscle support, rehabilitation, difficulty in swallowing and dysphagia, leg microcirculation, microbiota, enteral nutrition, tiredness and fatigue, memory and cognition, stress and sleep disorders, haemorrhoids, metabolic syndrome, cystic fibrosis, lesions, trauma and pain, and intestinal well-being. The website also maintains a reserved area for healthcare professionals and publishes editorial content on topics such as sarcopenic dysphagia, clinical nutrition and metabolic rehabilitation, branched-chain amino acids and HMB. The company is privately held and, on the evidence available, operates primarily in the Italian market. Its identity combines a legacy in cardiovascular pharmaceuticals with a more recent specialisation in therapeutic nutrition, a dual positioning that shapes both its product portfolio and its communication to clinicians.

Errekappa Euroterapici S.p.A. is an Italian pharmaceutical company based in Milan. Its official corporate history states that the business has a history of almost sixty years, originating in the 1960s, while the current joint-stock company (società per azioni) was constituted in 1989. That 1989 date is the one the company uses on its homepage when it describes itself as an Italian pharmaceutical company committed since 1989 to promoting innovative therapeutic solutions. The company's first phase of growth was in the cardiovascular sector. It became a reference company in that field through the launch of important molecules, including amlodipine (marketed under the name Antacal), doxazosin (Normothen) and atenolol (Atenol). These products established Errekappa's reputation among Italian clinicians and pharmacists and gave it a durable base in cardiovascular medicine. Between 2000 and 2014 the company continued its commitment to cardiovascular care, launching innovative fixed-dose combinations for hypertension. In the same period it broadened its portfolio beyond prescription pharmaceuticals into supplements, developing Riscol Plus for dyslipidemias and Anasten Plus for asthenia. In 2004 it launched Erreflog, a mouthwash based on nimesulide, extending its activity into a topical oral-care format. A decisive strategic shift came in 2007, when Errekappa turned its attention to clinical nutrition. The company set out to develop products with an interactive approach to malnutrition in patients with chronic pathologies. Preclinical and clinical studies, published in specialist journals in the field, demonstrated the capacity of a cluster of essential amino acids to interact positively with the use of nutritional substrates. This research programme produced Aminotrofic, which became a cornerstone of the company's clinical nutrition offering. In 2012 the company continued its commitment to clinical nutrition and, through ongoing research, launched Aminoglutam, a line of foods for special medical purposes intended for malnutrition in acute and sub-acute patients. This launch consolidated Errekappa's transition from a primarily cardiovascular pharmaceutical company into a company with a strong dual identity in pharmacology and therapeutic nutrition. In the years since, Errekappa has described itself as a point of reference in clinical nutrition and metabolic rehabilitation for more than twenty years, framing each of its solutions as the result of a constant effort to translate clinical evidence into effective therapeutic protocols for health professionals. Its website organises products around patient needs and conditions — muscle support, rehabilitation, dysphagia, leg microcirculation, microbiota, enteral nutrition, fatigue, memory and cognition, stress and sleep, haemorrhoids, metabolic syndrome, cystic fibrosis, lesions, trauma and pain, and intestinal well-being — and it maintains a reserved area for healthcare professionals alongside editorial content on clinical topics. The company remains privately held and, on the available evidence, focuses on the Italian market.

• 2023

  Website publishes articles on sarcopenic dysphagia and on clinical nutrition and metabolic rehabilitation.

• 2022

  Website publishes editorial content on branched-chain amino acids (BCAA) and HMB.

• 2012

  Launch of Aminoglutam, a line of foods for special medical purposes for malnutrition in acute and sub-acute patients.

• 2007

  Strategic turn to clinical nutrition; research on an essential amino acid cluster leads to the launch of Aminotrofic.

• 2004

  Launch of Erreflog, a nimesulide-based mouthwash.

• 1989

  The current joint-stock company Errekappa Euroterapici S.p.A. is constituted; the company dates its commitment to innovative therapeutic solutions from this year.

Italian pharmaceutical company positioning itself as a reference point in clinical nutrition and metabolic rehabilitation, combining pharmacological therapies with scientific nutrition for healthcare professionals and patients.

• Antacal

  Cardiovascular product based on amlodipine.

• Normothen

  Cardiovascular product based on doxazosin.

• Atenol

  Cardiovascular product based on atenolol.

• Riscol Plus

  Supplement developed for dyslipidemias.

• Anasten Plus

  Supplement developed for asthenia.

• Erreflog

  Nimesulide-based mouthwash launched in 2004.

• Aminotrofic

  Clinical nutrition product based on a cluster of essential amino acids, developed from 2007.

• Aminoglutam

  Line of foods for special medical purposes for malnutrition in acute and sub-acute patients, launched in 2012.

1. 1Errekappa | Soluzioni Terapeutiche e Nutrizione Scientificaerrekappa.it
2. 2Chi Siamo: Storia e Missione | Errekappaerrekappa.it
3. 3Errekappa Euroterapici S.p.A. (Italy) — Wikidatawikidata.org